Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 4:27 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 1,076 matching trials from the live ClinicalTrials.gov search.
Conditions
Cystic Fibrosis
Interventions
VX-121/TEZ/D-IVA, ELX/TEZ/IVA, IVA, Placebo (matched to VX-121/TEZ/D-IVA), Placebo (matched to ELX/TEZ/IVA), Placebo (matched to IVA)
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
597 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
62
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 55 more
Conditions
Pulmonary Fibrosis
Interventions
CC-90001
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
4
States / cities
Tampa, Florida • Michigan City, Indiana • Pittsburgh, Pennsylvania + 1 more
Conditions
Cystic Fibrosis
Interventions
azithromycin, placebo, Tobramycin solution for inhalation
Drug
Lead sponsor
Bonnie Ramsey
Other
Eligibility
6 Months to 18 Years
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
45
States / cities
Anchorage, Alaska • Tucson, Arizona • Little Rock, Arkansas + 40 more
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
GS-6624
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
40 Years to 85 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
7
States / cities
Scottsdale, Arizona • Los Angeles, California • Stanford, California + 4 more
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
HEC585
Drug
Lead sponsor
Sunshine Lake Pharma Co., Ltd.
Industry
Eligibility
18 Years to 60 Years
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Cystic Fibrosis
Interventions
Measurement of Sweat Chloride and Sweat Bromide
Diagnostic Test
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Hershey, Pennsylvania
Conditions
Interstitial Lung Diseases
Interventions
Not listed
Lead sponsor
Pulmonary Care and Research Collaborative Limited
Other
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 4 Interventional Results available

Pharmacokinetics of Omadacycline in Cystic Fibrosis

NCT04460586
Conditions
Cystic Fibrosis
Interventions
Omadacycline Injection [Nuzyra], Omadacycline Oral Tablet [Nuzyra]
Drug
Lead sponsor
Paul Beringer
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Completed No phase listed Observational Results available

IL-17 Neutrophils in CF Lung Inflammation

NCT02025829
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Cleveland, Ohio
Completed Not applicable Interventional Results available

Improving Vitamin D Status In Cystic Fibrosis

NCT00450073
Conditions
Cystic Fibrosis
Interventions
ergocalciferol (vitamin D2), Sperti Del Sol Lamp, Vitamin D3
Drug · Device
Lead sponsor
Atlanta VA Medical Center
Federal
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Cystic Fibrosis
Interventions
Ivacaftor, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
6 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
8
States / cities
Tampa, Florida • Atlanta, Georgia • Chicago, Illinois + 5 more
Conditions
Cystic Fibrosis, Lung Transplant; Complications
Interventions
Clinical Tool (Mobile Spirometry and Survey)
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Completed Phase 3 Interventional Results available

Study of Ataluren (PTC124™) in Cystic Fibrosis

NCT00803205
Conditions
Cystic Fibrosis
Interventions
Ataluren, Placebo
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
6 Years and older
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
21
States / cities
Birmingham, Alabama • Long Beach, California • Palo Alto, California + 16 more
Conditions
Cystic Fibrosis
Interventions
hypertonic saline (7%), isotonic saline
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis, Interstitial Pneumonitis, Desquamative Interstitial Pneumonia
Interventions
Aerobic Exercise Training (AET), Education
Other
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
21 Years to 80 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
2
States / cities
Bethesda, Maryland • Falls Church, Virginia
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Dayton Children's Hospital
Other
Eligibility
7 Years to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Dayton, Ohio
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
Up to 22 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Cystic Fibrosis-related Diabetes, Cystic Fibrosis
Interventions
Access to Dexcom G7 CGM Data
Device
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Conditions
Cystic Fibrosis
Interventions
Inhaled AR-501, Inhaled Placebo
Drug
Lead sponsor
Aridis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 49 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
25
States / cities
Tucson, Arizona • Long Beach, California • Denver, Colorado + 22 more
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Bacille Calmette-Guerin (BCG) Vaccine for Immune Protection Against Infections

NCT04884308
Conditions
Cystic Fibrosis, Bronchiectasis Adult, Non-Tuberculous Mycobacteria
Interventions
BCG TICE Vaccine
Biological
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Pirfenidone, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
435 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Brisbane, California
Conditions
Bronchiectasis, Pulmonary Disease, Chronic Obstructive
Interventions
Placebo to Ciprofloxacin DPI (BAYQ3939)
Drug
Lead sponsor
Bayer
Industry
Eligibility
40 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
2
States / cities
Vero Beach, Florida • Jamaica, New York
Conditions
Cystic Fibrosis
Interventions
VX-659/TEZ/IVA, IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
48
States / cities
Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 44 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of High Frequency Chest Wall Oscillation Vests on Spirometry Measurements

NCT03534986
Conditions
Cystic Fibrosis, Bronchiectasis
Interventions
International Biophysics AffloVest, Hill-Rom The Vest, Respirtech inCourage, Electromed SmartVest
Device
Lead sponsor
International Biophysics Corporation
Industry
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Kissimmee, Florida